| A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises |
Completed |
Inclacumab |
3 |
GBT2104-132 |
Prince Mohammad Bin Naser Hospital, Jizan, Saudi Arabi |
| Nucala Effectiveness Study (NEST) in Emerging Markets |
|
|
3 |
|
|
| Vitamin C as a potential ameliorating agent against hepatotoxicity among alcoholic abusers |
|
|
3 |
|
|
| The effect of (Oligonol) and (Oligonol + metformin) on the components of Metabolic Syndrome in obese individuals- A randomized, double-blind, factorial clinical trial. |
|
|
3 |
|
|
| An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A or B Patients With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis |
Ongoing |
PF-06741086 |
3 |
B7841005 |
King Abdulaziz University Hospital (Jeddah) |
| AN OPEN LABEL, SINGLE ARM, MULTICENTER,SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT |
|
|
3 |
|
|
| "An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) DELIVER - Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure " |
|
|
3 |
|
|
| Acute Effect of seaweed (Ecklonia cava extract) on blood glucose and insulin level in pre-diabetic patients: A double-blind randomized-controlled trial |
Ongoing |
Ecklonia cava extract |
3 |
SW2020 |
King Khalid University Hospital (Riyadh) |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER |
|
|
2 |
|
|
| A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis |
|
|
3 |
|
|
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.